Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis YoY Growth in the U.S.: 89.0% in FY2025, up 41.0 pts from a year earlier.
Latest, FY2025
89.0%
Period ended Dec 31, 2025
Change on a year earlier
+41.0 pts
48.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Scemblix | Oncology | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation | 824 | 89 | 461 | 82 | 78 | 1 285 | 87 | 85”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | YoY Growth in the U.S. (% USD / cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 89.0% | +41.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 48.0% | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.